



## Autologous Serum Tears are shown to help support corneal epithelial defects.<sup>1</sup>

### What are Autologous Serum Tears?

ASEDs or **Serum Tears** are customized drops made from a patient's own blood that is both a clinically effective and **cost-effective option** to support **nerve regeneration** and **healthier eyes**.<sup>2</sup> Opticyte Serum Tears contain ingredients that artificial tears do not, including **growth factors**, antibodies, albumin, and Vitamin A.<sup>3</sup> These all-natural preservative-free tears **improve and stabilize signs and symptoms** of patients with ocular defects.<sup>4</sup>


### How do Opticyte Tears work?

1. Your clinician issues a **Requisition** to Opticyte Tears via fax or email.
2. Our service team contacts you to schedule **in-clinic or at your home** Opticyte Serum Tears processing visit.
3. Only **Certified** Clinical Processing Specialist performs the procedure.
4. The Clinical Processing Specialist hands you your Opticyte Tear Serum in approximately **one hour**.

**It is that Easy.**

**Welcome to Easier Serum Tears.  
Opticyte Serum Tears.**

### Four Easy Steps



# OPTICYTE SERUM TEARS

**Opticyte**<sup>®</sup>  
Autologous Serum **Tears**

## Sizes (mL)

12, 5mL vials

8, 5mL vials

## Why Opticyte Serum Tears?

Opticyte Tears are the **best** way to provide autologous serum tears because of our commitment to **convenience, sterility, and your time.**

Our Clinical Processing Specialists are state licensed who are certified in our **unique sterile process** that provide up to 90-day supply of Opticyte Tears to the patient in **less than two hours**, either at home or in the clinic.

## Quality & Compliance

Opticyte Serum Tears adheres to national and state regulatory and compliance guidelines, including **USP Chapter 797.**

Components used in the preparation of Opticyte Tears are manufactured and sterility tested in accordance with **US FDA GMP regulations** as required by **21 CFR 820** and Part 200, Subpart C, Section 200.50 of **Title 21 of the U.S. Code of Federal Regulations.**



## References

1. Balal S, Nitiahpapand R, Hassan A, et al. Finger-prick autologous blood in the treatment of persistent corneal epithelial defects. *Cornea*. 2020;39(5):594-597
2. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499014/>
3. Quinto GG, Campos M, Behrens A. Autologous serum for ocular surface diseases. *Arq Bras Oftalmol*. 2008;71(6 Suppl):47-54.
4. Semeraro F, Forbice E, Braga O, Bova A, Di Salvatore A, Azzolini C. Evaluation of the efficacy of 50% autologous serum eye drops in different ocular surface pathologies. *Biomed Res Int*. 2014;2014;826970.